Types of percutaneous coronary interventions in ST-segment elevation myocardial infarction
https://doi.org/10.15829/1560-4071-2025-6369
EDN: ECNBUU
Abstract
In ST-segment elevation myocardial infarction (STEMI), various types of percutaneous coronary intervention (PCI) are performed depending on the disease duration, persistent disease symptoms, and prior thrombolytic therapy.
The aim of this review is to present all PCI types that can be performed in the treatment of patients with STEMI, substantiate the indications for their use, and the optimal option for endovascular intervention.
Basically, three following types of PCI used in patients with STEMI are distinguished: primary PCI (PPCI), late PCI (after 48 hours from the disease onset), and PCI after thrombolytic therapy. Different types of PCI in STEMI have different benefits. Current guidelines substantiate absolute indications for stenting with the highest level of evidence for 12-hour PPCI, rescue PCI, and routine early PCI after thrombolytic therapy. At the same time, the priority role in reperfusion in STEMI is assigned to 12-hour PPCI. That is why this indicator is a target in the European Stent for Life (SFL) initiative — the national/regional indicator of 12-hour PPCI should be 70% or higher of the number of patients hospitalized with STEMI.
About the Authors
O. L. Barbarash
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
Kemerovo
R. S. Tarasov
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
Kemerovo
A. I. Danilovich
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
Kemerovo
V. I. Ganyukov
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
Kemerovo
References
1. Ibanez B, James S, Agewall S, et al.; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. doi:10.1093/eurheartj/ehx393.
2. Averkov OV, Harutyunyan GK, Duplyakov DV, et al. 2024 Clinical practice guidelines for Acute myocardial infarction with ST segment elevation electrocardiogram. Russian Journal of Cardiology. 2025;30(3):6306. (In Russ.) doi:10.15829/1560-4071-2025-6306.
3. Silber S, Albertsson P, Avilés FF, et al. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26(8):804-47. doi:10.1093/eurheartj/ehi138.
4. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31(20):2501-55. doi:10.1093/eurheartj/ehq277.
5. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569-619. doi:10.1093/eurheartj/ehs215.
6. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-¬Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541-619. doi:10.1093/eurheartj/ehu278.
7. Byrne RA, Rossello X, Coughlan JJ, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-826. doi:10.1093/eurheartj/ehad191.
8. Averkov OV, Duplyakov DV, Gilyarov MYu, et al. Acute myocardial infarction with ST segment elevation electrocardiogram. Clinical Recommendations 2020. Russian Journal of Cardiology. 2020;25(11):4103. (In Russ.) doi:10.15829/1560-4071-2020-4103. EDN: KNQWWK.
9. Alekyan BG, Boytsov SA, Manoshkina EM, Ganyukov VI. Analysis of Russian national indicators of myocardial revascularization in patients with acute coronary syndrome in 2022. "Endovascular surgery". 2023;10(3):260-9. (In Russ.)
10. Alekyan BG, Boytsov SA, Ganyukov VI, Manoshkina EM. The impact of the COVID-19 pandemic on myocardial revascularization in patients with acute coronary syndrome in the Russian Federation. Rational pharmacotherapy in cardiology. 2022;18(4):411-9. (In Russ.) doi:10.20996/1819-6446-2022-08-03.
11. Alekyan BG, Boytsov SA, Manoshkina EM, Ganyukov VI. Myocardial revascularization in the Russian Federation in acute coronary syndrome in 2016-2020. Cardiologiia. 2021;61(12):4-15. (In Russ.)
12. Alekyan BG, Ganyukov VI, Manoshkina EM, et al. Revascularization in ST-segment elevation myocardial infarction in the Russian Federation. Analysis of the 2018 results. Endovascular surgery. 2019;6(2):89-97. (In Russ.)
13. Stent for life. How to guide. Stent for Life is a joint initiative between the European Association of Percutaneous Cardiovascular Interventions (EAPCI), a registered branch of the European Society of Cardiology (ESC), and EuroPCR. doi:10.13140/RG.2.1.2158.2801.
14. Keeley EC, Boura JA, Grines CL, et al. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction a quantitative review of 23 randomized trials. Lancet. 2003;361:13-20.
15. Huynh T, Perron S, O’Loughlin J, et al. Comparison of primary percutaneous coronary intervention and fibrinolytic therapy in ST-segment-¬elevation myocardial infarction: baye¬sian hierarchical meta-analyses of randomized controlled trials and observational studies. Circulation. 2009;119(24):3101-9. doi:10.1161/CIRCULATIONAHA.108.793745.
16. Barbarash LS, Ganyukov VI. Organization and tactics of percutaneous coronary intervention in ST-segment elevation myocardial infarction. Kemerovo, 2012. 230 p. (In Russ.
17. Armstrong P, Gershlick A, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368:1379-87. doi:10.1056/NEJMoa1301092.
18. Van de Werf F, Ristić AD, Averkov OV, et al. STREAM-2 Investigators. STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial. Circulation. 2023;148(9):753-64. doi:10.1161/CIRCULATIONAHA.123.064521.
19. Danchin N, Popovic B, Puymirat E, et al. FAST-MI Investigators. Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme. Eur Heart J. 2020;41(7):858-66. doi:10.1093/eurheartj/ehz665.
20. Bainey K, Armstrong P, Zheng Y, et al. Pharmacoinvasive strategy versus primary percutaneous coronary intervention in ST-elevation myocardial infarction in clinical practice insights from the Vital Heart Response Registry. Circ Cardiovasc Interv. 2019;12:e008059. doi:10.1161/CIRCINTERVENTIONS.119.008059.
21. Danchin N, Coste P, Ferriиres J, et al.; FAST-MI Investigators. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the French registry on Acute ST-elevation Myocardial Infarction (FAST-MI). Circulation. 2008;118:268-76. doi:10.1161/CIRCULATIONAHA.107.762765.
22. Danchin N, Puymirat E, Steg PG, et al. FAST-MI 2005 Investigators. Five-year survival in patients with ST-segment-¬elevation myocardial infarction according to modalities of reperfusion therapy: the French Registry on Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) 2005 Cohort. Circulation. 2014;129:1629-36. doi:10.1161/CIRCULATIONAHA.113.005874.
23. Rashid MK, Guron N, Bernick J, et al. Safety and efficacy of a pharmacoinvasive strategy in ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2016;9:2014-2020. doi:10.1016/j.jcin.2016.07.004.
24. Siontis KC, Barsness GW, Lennon RJ, et al. Pharmacoinvasive and Primary Percutaneous Coronary Intervention Strategies in ST-Elevation Myocardial Infarction (from the Mayo Clinic STEMI Network). Am J Cardiol. 2016;117:1904-10. doi:10.1016/j.amjcard.2016.03.036.
25. Sim DS, Jeong MH, Ahn Y, et al. Korea Acute Myocardial Infarction Registry (KAMIR) Investigators. Pharmacoinvasive strategy versus primary percutaneous coronary intervention in patients with ST-segment–elevation myocardial infarction. Circ Cardiovasc Interv. 2016;9:e003508. doi:10.1161/CIRCINTERVENTIONS.115.003508.
26. Jamal J, Idris H, Faour A, et al. Late outcomes of ST-elevation myocardial infarction treated by pharmaco-invasive or primary percutaneous coronary intervention. European Heart Journal. 2023;44(6):516-28. doi:10.1093/eurheartj/ehac661.
27. Jortveit J, Pripp AH, Halvorsen S, et al. Outcomes after delayed primary percutaneous coronary intervention vs. pharmaco-invasive strategy in ST-segment elevation myocardial infarction in Norway. European Heart Journal. Cardiovascular Pharmacotherapy. 2022;8(5):442-51. doi:10.1093/ehjcvp/pvab041.
28. Boytsov SA, Alekyan BG, Shakhnovich RM, Ganyukov VI. What is changing in the treatment of acute coronary syndrome in the Russian Federation? Rational Pharmacotherapy in Cardiology. 2022;18(6):703-9. (In Russ.)
29. Gierlotka M, Gasior M, Wilczek K, et al. Reperfusion by primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction within 12 to 24 hours of the onset of symptoms (from a prospective national observational study [PL-ACS]). Am J Cardiol. 2011;107:501-8. doi:10.1016/j.amjcard.2010.10.008.
30. Schömig A, Mehilli J, Antoniucci D, et al. Beyond 12 hours Reperfusion AlternatiVe Evaluation (BRAVE-2) Trial Investigators. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005;293(23):2865-72. doi:10.1001/jama.293.23.2865.
31. Ndrepepa G, Kastrati A, Mehilli J, et al. Mechanical reperfusion and long-term mortality in patients with acute myocardial infarction presenting 12 to 48 hours from onset of symptoms. JAMA. 2009;301(5):487-8.
32. Bouisset F, Gerbaud E, Bataille V, et al. Percutaneous myocardial revascularization in late-presenting patients with STEMI. J Am Coll Cardiol. 2021;78:1291-305. doi:10.1016/j.jacc.2021.07.039.
33. Busk M, Kaltoft A, Nielsen SS, et al. Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for <12 h vs. 12-72 h. Eur Heart J. 2009;30(11):1322-30. doi:10.1093/eurheartj/ehp113.
34. Aggarwal P, Rekwal L, Sinha SK, et al. Predictors of no-reflow phenomenon following percutaneous coronary intervention for ST-segment elevation myocardial infarction. Ann Cardiol Angeiol (Paris). 2021;70(3):136-42. doi:10.1016/j.ancard.2021.04.004.
35. Hochman JS, Lamas GA, Buller CE, et al. Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355(23): 2395-407. doi:10.1056/NEJMoa066139.
36. Menon V, Pearte CA, Buller CE, et al. Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial. Eur Heart J. 2009;30:183-91. doi:10.1093/eurheartj/ehn486.
37. Ioannidis JP, Katritsis DG. Percutaneous coronary intervention for late reperfusion after myocardial infarction in stable patients. Am Heart J. 2007;154(6):1065-71. doi:10.1016/j.ahj.2007.07.049.
38. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407-77. doi:10.1093/eurheartj/ehz425.
39. Gershlick AH, Stephens-Lloyd A, Hughes S, et al. REACT Trial Investigators. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med. 2005;353(26):2758-68. doi:10.1056/NEJMoa050849.
40. Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360:2705-18. doi:10.1056/NEJMoa0808276.
41. Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet. 2008;371:559-68. doi:10.1016/s0140-6736(08)60268-8.
42. Bøhmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and safety of immediate angioplasty versus ischemia-¬guided management after thrombolysis inacute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol. 2010;55:102-10. doi:10.1016/j.jacc.2009.08.
43. Cho KH, Han X, Ahn JH, et al. Long-term outcomes of patients with late presentation of ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77:1859-70.
Supplementary files
- The review presents all types of percutaneous coronary intervention (PCI) used in patients with ST-segment elevation myocardial infarction (STEMI).
- Endovascular interventions for STEMI are divided depending on the disease duration, persistent symptoms of the disease, and the preliminary use of thrombolytic therapy.
- Different types of PCI for STEMI have different benefits.
- The review, based on the evidence base, substantiates the priority role of primary PCI within 12 hours from the symptom onset among all types of reperfusion in patients with STEMI, which has been enshrined in modern guidelines since 2003.
Review
For citations:
Barbarash O.L., Tarasov R.S., Danilovich A.I., Ganyukov V.I. Types of percutaneous coronary interventions in ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2025;30(9S):6369. (In Russ.) https://doi.org/10.15829/1560-4071-2025-6369. EDN: ECNBUU
Views:
301
Email this article 